Strong topline, margin compression, pipeline-rich transformation story

Revenue ₹466 Cr (+45% YoY). All segments contributed: Formulation +112%, API +15%, Biologics +42%. But QoQ revenue +6.6%, PAT -6.4%, indicating margin deterioration.

Domestic Formulation revenue dipped QoQ despite product launched Q3 FY26. Management refuses product-level disclosure, deflects to 'stocking variation.' Analyst skepticism evident on 6-month ramp trajectory.

EBITDA margin 30%, EBITDA PAT 21.5% (vs. 29.3% OPM delivered). Gross margin 71%, down YoY due to raw material inflation. QoQ margin compressed despite 6.6% revenue growth.

Capex ₹114 Cr/Q (₹456 Cr annualized, ~98% of Q1 revenue). Self-funded via internal accruals, but remains heavy. Not 'largely behind.'

Included in Formulation +112% growth. Individual product metrics not disclosed; cannot independently verify trajectory or sustainability.

Prior call: 'Product launches and capacity expansions from FY27 onwards.' This call: 'Healthy steady growth, faster profitability.' No numeric targets provided; more cautious tone.

3 late-stage programs now visible to enter commercialization FY28. Improves confidence on near-term revenue inflection vs. prior vague 'multiple programs' language.

No expansion guidance given. Management emphasizes 'conservative and overdeliver,' expects range ~30% EBITDA. Gross margin headwinds (FX, raw materials) being managed, not overcome.

₹114 Cr/Q capex for Biologics, Albumin, API completion. 'Self-funded' but represents ~₹450 Cr annually. Consistent with transformation narrative but high burn rate.

Biologics and Formulations have low utilization, room for growth. API high-utilization justifies incremental capex. Mix of both keeps capital deployed for growth.

Cannot provide specific guidance. Expect healthy steady growth from Biologics and niche Formulations monetization. Main barrier: regulatory pathway risk.

Do not disclose product-level numbers. Strong order trajectory. Clinical data published online; Phase IV ongoing.

Operational question, can discuss offline. Strong mixed team with consultants on US/EU regulations. No specific roadmap disclosed.

Innovative CDMO.

Confidentiality on program; will share details in upcoming call.

Not a product-level detail. Stocking and manufacturing schedules vary quarter-to-quarter. Product overall doing well.

Sizable business. Won't disclose target. Have 25+ NCE programs, 1 commercial today. Growth will depend on program advancement.

Depends on partner. Visibility next year: 3 NCE programs entering commercial phase.

Yes, you are right.

Complex products (Rotigotine, Abraxane, NCEs, 505b2s) drive margins. Raw material inflation (global politics) pressure; partial pass-through to customers.

Difficult to quantify; pass-through to customer varies. Timing difference based on contract positioning.

R&D units fully built; no significant future R&D capex expected. Effective tax rate benefit (~10%) outweighs lost depreciation. Leveraging MAT credit.

Not selling me-too generics to US; all complex products. Monitoring Trump administration stance. No immediate US facility plan.

Tendered products; quarter-to-quarter supply variation normal. No structural dip; product and market performing well.

Connect with Monish (IR Head) for segmental utilization details.

Biologics: 8 biosimilars not yet partnered (vs. 1 Nivolumab in Europe). Albumin: Phase I done, starting Phase III globally, already partnered in Europe. Potential significant. Won't quantify segment-wise ROCE.

Cannot segregate numbers. Licensing fees significantly higher than R&D spend. Project-dependent, non-recurring. Mixed with continuous development cycles.

B2B model: we develop products and license out. No in-market presence. More portfolio development = more licensing opportunity.

20+ CDMO customers across Shilpa Group.

Doing well in India via partner with strong arthritis reach. Not a big opportunity; first product to prove capability. Moving to complex products (Aflibercept, Nivolumab).

Do not disclose product-level numbers. Complexity and differentiation vs. generics key to sustainability. Good long-term opportunity.

Mix. Rotigotine: first-wave generic. Abraxane: second-wave (few players but complex, tender-featured). Select only products with sustainable long-term growth.

Oncology API growth depends on end-customer adoption and molecules commoditizing timeline. Visibility on end-customer interest already. Formulation: 50%+ captive from internal APIs.

Mixed strategy. Short-to-mid term: biosimilars and CDMO. Long term: strategic partnerships (Alveolus, mAbTree) for longer-term bets with significant upside.

No client/product-specific disclosure. Connect with Monish for whatever details possible.

Management says 'healthy and steady growth' from pipeline launches (Formulation FY27-28, CDMO FY28). Implies low-to-mid 20s growth, but unquantified.

Acknowledges raw material headwinds. Says 'conservative and overdeliver' approach; won't commit to expansion.

But admits FX/commodity pressure ongoing. Partial pass-through to customers. Sustainability depends on normalization.

Says 'no significant capex for next 3 years' in Biologics/Albumin post-FY27. API and select Formulation capex to continue.

Formulation launches (Rotigotine FY28, Abraxane/Enzalutamide/Abiraterone FY28) and Biologics launches (Aflibercept FY27, Nivolumab FY28) core to growth thesis. Any delay would materially impact near-term revenue and margin recovery.

Gross margin 71%, down from 75%+ due to raw material inflation (political disruptions) and FX headwinds. QoQ PAT -6.4% despite revenue +6.6% signals cost pressure overcoming volume gains. If headwinds persist, EBITDA margin could compress below 30%.

Nor-UDCA, positioned as NCE growth driver, showed domestic revenue dip QoQ despite 6-month post-launch. Management claims stocking variation, but analyst skepticism evident. Emcure's semaglutide approval for NAFLD could limit Nor-UDCA opportunity. Global Phase II just starting FY27; commercialization 2+ years away.

CDMO business has 20+ customers but only 1 commercial product. Revenue dependent on partner execution (programs run by partner, not Shilpa). Most programs Phase I-II, 2-5 years to commercialization. Loss of key partner or major program delay would impact near-term revenue.

Complex formulations and biologics subject to evolving regulatory standards. Any manufacturing issue or product safety event could delay launches or trigger recalls. U.S. tariff threat (₹45 Cr exports, ~10% of revenue) on generic drugs, though management downplays impact on complex products.